

Neuro aktuell

Ausgabe 8-2020

Literatur

Schwerpunkt: Schlaganfall

Titel: Neurologische Rehabilitation nach Schlaganfall (S. 7–15)

Autorin: J. Lamprecht, M. Sailer

Literatur:

1. Bundesarbeitsgemeinschaft für Rehabilitation. Empfehlungen zur Neurologischen Rehabilitation von Patienten mit schweren und schwersten Hirnschädigungen in den Phasen B und C. Frankfurt: BAR; 1995
2. Mahoney FI & Barthel DW. Functional Evaluation: The Barthel Index. Md State Med J 1965; 14: 61–65
3. Schönle PW. Frühe Phasen der Neurologischen Rehabilitation: Differentielle Schweregradbeurteilung bei Patienten in der Phase B (Frührehabilitation) und in der Phase C (Frühmobilisation/Postprimäre Rehabilitation) mit Hilfe des Frühreha-Barthel-Index (FRB). Neurol Rehabil 1996; 21–25
4. Keith RA et al. The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil 1987; 1: 6–18
5. World Health Organization. ICF-International Classification of Functioning, Disability and Health. Geneva: WHO; 2001
6. Pascual-Leone A et al. The Plastic Human Brain Cortex. Annu Rev Neurosci 2005; 28:377–401
7. Kreisel SH et al. Pathophysiology of Stroke Rehabilitation: Temporal Aspects of Neurofunctional Recovery. Cerebrovasc Dis 2006; 21: 6–17
8. Carey L et al. Finding the Intersection of Neuroplasticity, Stroke Recovery, and Learning: Scope and Contributions to Stroke Rehabilitation. Neural Plast 2019; Article ID 5232374
9. Platz T. Update Neurorehabilitation. Bad Honnef: Hippocampus Verlag; 2016
10. Elbert T & Rockstroh B. Reorganization of Human Cerebral Cortex: The Range of Changes following Use and Injury. The Neuroscientist 2004; 10 (2): 129–141
11. Nelles G et al. Rehabilitation von sensomotorischen Störungen, S2k-Leitlinie, 2018, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. www.dgn.org/leitlinien (abgerufen am 01.10.2020)
12. Thöne-Otto A et al. Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen, S2e-Leitlinie, 2020, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. www.dgn.org/leitlinien (abgerufen am 01.10.2020)
13. Karnath HO et al. S1-Leitlinie Rehabilitation bei Störungen der Raumkognition 2017. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. www.dgn.org/leitlinien (abgerufen am 01.10.2020)
14. Müller SV et al., Diagnostik und Therapie von exekutiven Dysfunktionen bei neurologischen Erkrankungen, S2e-Leitlinie, 2019, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. www.dgn.org/leitlinien (abgerufen am 01.10.2020)

15. Sunderland A et al. Enhanced physical therapy for arm function after stroke: a one year follow up study. *J Neurol Neurosurg Psychiatry* 1994; 57: 856–858
16. Platz T & Roschka S. Rehabilitative Therapie bei Armparese nach Schlaganfall. *Neurol Rehabil* 2009; 15 (2): 81–106
17. Dohle C et al. S2e-Leitlinie »Rehabilitation der Mobilität nach Schlaganfall (ReMoS). *Neurol Rehabil* 2015; 21(4): 179–184. DOI: 10.14624/NR201509.001
18. Lang CE et al. Dose and timing in neurorehabilitation: Prescribing motor therapy after stroke. *Curr Opin Neurol* 2015; 28(6): 549–555
19. Lamprecht J et al. Einfluss kognitiver Dysfunktionen auf die Motorik und Mobilität im Verlauf der neurologischen Rehabilitation nach Schlaganfall. *DRV Schriften* 2020; Bd. 120: 165–16
20. Ziegler WF et al. Rehabilitation aphasischer Störungen nach Schlaganfall. In H. D. Diener & N. Putzki (Eds.), *Leitlinien für Diagnostik und Therapie in der Neurologie*. Stuttgart: Thieme 2012
21. Huber W et al. *Aachener Aphasie Test (AAT)*. Göttingen: Hogrefe; 1983
22. Glindemann R et al. Aphasie und Kommunikation. In: Goldberg, G., Pössl, J., Ziegler, W. (eds.). *Neuropsychologie im Alltag*. Stuttgart: Thieme 2002: 78–97
23. Sickert A et al. Constraint-induced aphasia therapy following sub-acute stroke: a single-blind, randomised clinical trial of a modified therapy schedule. *JNNP* 2014; 85(1): 51–5
24. Dziewas R et al. Neurogene Dysphagie, S1-Leitlinie, 2020, in: Deutsche Gesellschaft für Neurologie (Hrsg.), *Leitlinien für Diagnostik und Therapie in der Neurologie*. www.dgn.org/leitlinien (abgerufen am 01.10.2020)
25. Schröter-Morasch H. *Anamnesebogen zur klinischen Erfassung von Schluckstörungen nach Hirnverletzungen*. Dortmund: Bergmann-Publishing; 1994
26. Belafsky PC et al. Validity and reliability of the Eating Assessment Tool (EAT-10). *The Annals of otology, rhinology, and laryngology* 2008; 117(12): 919–24
27. Bartolome G & Schröter-Morasch H, editors. *Schluckstörungen Interdisziplinäre Diagnostik und Rehabilitation*. München: Elsevier, Urban & Fischer; 2018a. 403–32
28. Ickenstein GW et al. Standardisierung des Untersuchungsablaufs bei Neurogener Oropharyngealer Dysphagie (NOD). *Neuro Rehabil* 2009; 15 (5): 290–300
29. Perry L. Screening swallowing function of patients with acute stroke. Part one: identification, implementation and initial evaluation of a screening tool for use by nurses. *Journal of Clinical Nursing* 2001; 10: 463–473
30. Daniels SK et al. Clinical assessment of swallowing and prediction of dysphagia severity. *Am J Speech Lang Pathol* 1997; 6: 17–24
31. Deutsche Rentenversicherung. *Rahmenkonzept Nachsorge (Fassung 1.Juli 2019)*. https://www.deutsche-rentenversicherung.de/SharedDocs/Downloads/DE/Experten/infos_reha_einrichtungen/konzepte_systemfragen/konzepte/rahmenkonzept_reha_nachsorge.html (abgerufen am 01.10.2020)

Schwerpunkt: Schlafstörungen

Titel: Chronotherapeutika bei neurodegenerativen Erkrankungen (S. 22–32)

Autorin: A. Wahnschaffe, D. Kunz

Literatur:

1. Burns A et al. Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behaviour. *Br J Psychiatry* 1990; 157: 86–94
2. Spira AP et al. Objectively measured sleep quality and nursing home placement in older women. *J Am Geriatr Soc* 2012; 60: 1237–1243
3. Hut RA & Beersma DG. Evolution of time-keeping mechanisms: early emergence and adaptation to photoperiod. *Philos Trans R Soc Lond B Biol Sci* 2011; 366: 2141–2154
4. Lucas RJ et al. Regulation of the mammalian pineal by non-rod, non-cone, ocular photoreceptors. *Science* 1999; 284: 505–507
5. Altimus CM et al. Rod photoreceptors drive circadian photoentrainment across a wide range of light intensities. *Nat Neurosci* 2010; 13: 1107–1112
6. Hardeland R & Poeggeler B. Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system. *Cent Nerv Syst Agents Med Chem* 2012; 12: 189–216
7. Dubocovich ML & Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. *Endocrine* 2005; 27: 101–110
8. Aschoff J. Human circadian rhythms in activity, body temperature and other functions. *Life Sci Space Res* 1967; 5: 159–173
9. Brown SA et al. Molecular insights into human daily behavior. *Proc Natl Acad Sci U S A* 2008; 105: 1602–1607
10. Mislberger RE & Bergmann BM, Rechtschaffen A. Relationships among wake episode lengths, contiguous sleep episode lengths, and electroencephalographic delta waves in rats with suprachiasmatic nuclei lesions. *Sleep* 1987; 10: 12–24
11. Kunz D. Editorial: Circadian Rhythms are Everywhere: Except in Neurodegenerative Disorders. *Curr Alzheimer Res* 2017; 14: 1018–1021
12. Kraemer WJ et al. The effects of a roundtrip trans-American jet travel on physiological stress, neuromuscular performance, and recovery. *J Appl Physiol (1985)* 2016; 121: 438–443
13. Golombek DA et al. The times they're a-changing: effects of circadian desynchronization on physiology and disease. *J Physiol Paris* 2013; 107: 310–322
14. de Zeeuw J et al. Living in biological darkness: objective sleepiness and the pupillary light responses are affected by different metameric lighting conditions during daytime. *J Biol Rhythms* 2019; 34: 410–431
15. Wahnschaffe A et al. Out of the lab and into the bathroom: evening short-term exposure to conventional light suppresses melatonin and increases alertness perception. *Int J Mol Sci* 2013; 14: 2573–2586
16. World Health Organization. Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 10. Revision, German Modification, Version 2020
17. Ittner LM, Götz J. Amyloid-((beta)) β and tau – a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci* 2011; 12: 65–78
18. Van Hoesen GW et al. Entorhinal cortex pathology in Alzheimer's disease. *Hippocampus* 1991; 1: 1–9
19. Videnovic A et al. ,The clocks that time us'--circadian rhythms in neurodegenerative disorders. *Nat Rev Neurol* 2014; 10: 683–693
20. Sellix MT et al. Aging differentially affects the reentrainment response of central and peripheral circadian oscillators. *J Neurosci* 2012; 32: 16193–16202
21. Weitzman ED et al. Chronobiology of aging: temperature, sleep-wake rhythms and entrainment. *Neurobiol Aging* 1982; 3: 299–309
22. Touitou Y et al. Adrenal circadian system in young and elderly human subjects: a comparative study. *J Endocrinol* 1982; 93: 201–210

23. Mahlberg R et al. Pineal calcification in Alzheimer's disease: an in vivo study using computed tomography. *Neurobiol Aging* 2008; 29: 203–209
24. Cohen-Mansfield J et al. Sleep and agitation in agitated nursing home residents: an observational study. *Sleep* 1995; 18: 674–680
25. Alhawassi TM et al. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. *Clin Interv Aging* 2014; 9: 2079–2086
26. Tranah GJ et al.; SOF Research Group. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. *Ann Neurol* 2011; 70: 722–732
27. Liu RY et al. Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression. *J Neuropathol Exp Neurol* 2000; 59: 314–322
28. Swaab DF et al. The vasopressin containing neurons in the human brain; changes during ageing and senile dementia. *Br J Clin Pract Suppl* 1985; 39: 7–10
29. Kunz D et al. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. *Neuropsychopharmacology* 1999; 21: 765–772
30. Turner PL et al. The role of environmental light in sleep and health: effects of ocular aging and cataract surgery. *Sleep Med Rev* 2010; 14: 269–280
31. Scherder EJ et al. The more physical inactivity, the more agitation in dementia. *Int Psychogeriatr* 2010; 22: 1203–1208
32. Busche MA et al. Wie Schlaf und Alzheimer- Krankheit zusammenhängen: Insomnie, Amnesie und Amyloid. *Nervenarzt* 2016; 88: 215–221
33. Spillantini MG et al. Alpha-synuclein in Lewy bodies. *Nature* 1997; 388: 839–840
34. Schenck CH et al. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. *Sleep* 1986; 9: 293–308
35. Ito E & Inoue Y. [The International Classification of Sleep Disorders, third edition. American Academy of Sleep Medicine. Includes bibliographies and index]. *Nihon Rinsho* 2015; 73: 916–923
36. Olson EJ et al. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. *Brain* 2000; 123: 331–339
37. Haba-Rubio J et al. Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population. *Sleep* 2018; 41: pii: zsx197
38. Schenck CH et al. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. *Neurology* 1996; 46: 388–393
39. Postuma RB et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain* 2019; 142: 744–759
40. McCarter SJ et al. REM sleep muscle activity in idiopathic REM sleep behavior disorder predicts phenocconversion. *Neurology* 2019; 93: e1171–e1179
41. Videnovic A et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. *JAMA Neurol* 2014; 71: 463–469
42. Videnovic A & Golombek D. Circadian Dysregulation in Parkinson's Disease. *Neurobiol Sleep Circadian Rhythms* 2017; 2: 53–58
43. Paech GM et al. The relative contributions of the homeostatic and circadian processes to sleep regulation under conditions of severe sleep restriction. *Sleep* 2012; 35: 941–948
44. Bussi IL, Levín G, Golombek DA, Agostino PV. Involvement of dopamine signaling in the circadian modulation of interval timing. *Eur J Neurosci* 2014; 40: 2299–2310.
45. Sleipness EP et al. Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus. *Brain Res* 2007; 1129: 34–42
46. van Gilst MM et al. „Sleep benefit“ in Parkinson's disease: a systematic review. *Parkinsonism Relat Disord* 2013; 19: 654–659

47. de Pedro-Cuesta J & Stawiarz L. Parkinson's disease incidence: magnitude, comparability, time trends. *Acta Neurol Scand* 1991; 84: 382–388
48. Lewy AJ et al. Melatonin shifts human circadian rhythms according to a phase-response curve. *Chronobiol Int* 1992; 9: 380–392
49. Khalsa SB et al. A phase response curve to single bright light pulses in human subjects. *J Physiol* 2003; 549: 945–952
50. Archer SN et al. Mistimed sleep disrupts circadian regulation of the human transcriptome. *Proc Natl Acad Sci U S A* 2014; 111: E682–E691
51. Touitou Y et al. Association between light at night, melatonin secretion, sleep deprivation, and the internal clock: Health impacts and mechanisms of circadian disruption. *Life Sci* 2017; 173: 94–106
52. Herxheimer A & Petrie KJ. Melatonin for the prevention and treatment of jet lag. *Cochrane Database Syst Rev* 2002; 2: CD001520
53. Mahlberg R et al. Degree of pineal calcification (DOC) is associated with polysomnographic sleep measures in primary insomnia patients. *Sleep Med* 2009; 10: 439–445
54. Kunz D & Mahlberg R. Melatonin: a chronobiotic that not only shifts rhythms. In: Lader M, Cardinali DP, Pandi-Perumal SR, eds. *Sleep and sleep disorders: a neuropsychopharmacological approach*. New York: Springer 2006; 100–106
55. Wu YH & Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. *Sleep Med* 2007; 8: 623–636
56. Swaab DF et al. Brain aging and Alzheimer's disease; use it or lose it. *Prog Brain Res* 2002; 138: 343–373
57. Wahnschaffe A et al. Night-time activity forecast by season and weather in a longitudinal design – natural light effects on three years' rest-activity cycles in nursing home residents with dementia. *Int Psychogeriatr* 2017; 29: 2071–2080
58. Lahiri DK et al. Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. *J Pineal Res* 2004; 36: 224–231
59. Matsubara E et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. *J Neurochem* 2003; 85: 1101–1108
60. Zeitzer JM et al. Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. *J Physiol* 2000; 526: 695–702
61. Kunz D et al. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. *J Clin Endocrinol Metab* 2004; 89: 128–134
62. Münch M et al. Bright Light Delights: Effects of Daily Light Exposure on Emotions, Restactivity Cycles, Sleep and Melatonin Secretion in Severely Demented Patients. *Curr Alzheimer Res* 2017; 14: 1063–1075
63. Mahlberg R et al. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. *J Clin Psychopharmacol* 2004; 24: 456–459
64. Mishima K et al. Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. *Acta Psychiatr Scand* 1994; 89: 1–7
65. Ancoli-Israel S et al. Effect of light treatment on sleep and circadian rhythms in demented nursing home patients. *J Am Geriatr Soc* 2002; 50: 282–289
66. Burns A et al. Bright light therapy for agitation in dementia: a randomized controlled trial. *Int Psychogeriatr* 2009; 21: 711–721
67. Skjerve A et al. Improvement in behavioral symptoms and advance of activity acrophase after short-term bright light treatment in severe dementia. *Psychiatry Clin Neurosci* 2004; 58: 343–347

68. Van Someren EJ. Actigraphic monitoring of movement and rest-activity rhythms in aging, Alzheimer's disease, and Parkinson's disease. *IEEE Trans Rehabil Eng* 1997; 5: 394–398
69. Riemersma-van der Lek RF et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. *JAMA* 2008; 299: 2642–2655
70. van Hoof J et al. High colour temperature lighting for institutionalised older people with dementia. *Build Environ* 2009; 44: 1959–1969
71. Hopkins S et al. Blue-Enriched Lighting for Older People Living in Care Homes: Effect on Activity, Actigraphic Sleep, Mood and Alertness. *Curr Alzheimer Res* 2017; 14: 1053–1062
72. Hankins MW et al. Melanopsin: an exciting photopigment. *Trends Neurosci* 2008; 31: 27–36
73. Chahine LM et al. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. *Sleep Med Rev* 2017; 35: 33–50
74. Postuma RB et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. *Ann Neurol* 2015; 77: 830–839
75. Kunz D & Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. *Mov Disord* 1999; 14: 507–511
76. Takeuchi N et al. Melatonin therapy for REM sleep behavior disorder. *Psychiatry Clin Neurosci* 2001; 55: 267–269
77. Anderson KN & Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. *J Clin Sleep Med* 2009; 5: 235–239
78. Schaefer C et al. Melatonin Effects in REM Sleep Behavior Disorder Associated with Obstructive Sleep Apnea Syndrome: A Case Series. *Curr Alzheimer Res* 2017; 14: 1084–1089
79. Kunz D & Bes F. Melatonin Therapy of RBD. In: Schenck CH, Högl B, Videnovic A, eds. *Rapid-Eye-Movement Sleep Behavior Disorder*. Cham: Springer 2019; 315–331
80. Videnovic A et al. Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial. *JAMA Neurol* 2017; 74: 411–418